cilostazol has been researched along with Parkinson Disease in 2 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Sayed, RM | 1 |
| Abdelaziz, AM | 1 |
| Zaki, HF | 1 |
| Abdel Rasheed, NO | 1 |
| Hedya, SA | 1 |
| Safar, MM | 1 |
| Bahgat, AK | 1 |
2 other studies available for cilostazol and Parkinson Disease
| Article | Year |
|---|---|
Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling.
Topics: Animals; Cilostazol; HMGB1 Protein; Mammals; Neuroprotection; Neuroprotective Agents; NF-E2-Related | 2023 |
Cilostazol Mediated Nurr1 and Autophagy Enhancement: Neuroprotective Activity in Rat Rotenone PD Model.
Topics: Animals; Apoptosis; Autophagy; Behavior, Animal; Biomarkers; Cilostazol; Disease Models, Animal; Gly | 2018 |